Citadel Advisors
EBACU

Citadel Advisors’s European Biotech Acquisition Corp. Units EBACU Stock Holding History

Citadel Advisors’s Portfolio EBACU Stock Details EBACU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-625,000
Closed -$6.28M – 14731
2021
Q1 		$6.28M Buy
+625,000
New +$6.25M ﹤0.01% 3789

Other funds holding EBACU

Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $1.14B AUM 6.91% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return
ACA
Arena Capital Advisors Los Angeles, California $208M AUM 11.42% 1-Year Est. Return
FTCM
First Trust Capital Management Chicago, Illinois $1.72B AUM 70.66% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $3.04B AUM 26.78% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Citadel Advisors's EBACU Position: Q2 2021 in Review

Citadel Advisors sold out of European Biotech Acquisition Corp. Units (EBACU) in Q2 2021, closing a stake of 625,000 shares — an estimated $6.28M sold.

Citadel Advisors first reported a position in EBACU in Q1 2021 and held it in 1 quarter. The position peaked at $6.28M in Q1 2021. 37 funds tracked by Wall St. Rank hold EBACU as of Q2 2021.

  • Citadel Advisors reported no remaining European Biotech Acquisition Corp. Units position as of Q2 2021 after selling out during the quarter.
  • Citadel Advisors sold 625,000 European Biotech Acquisition Corp. Units shares in Q2 2021, an estimated $6.28M.
  • Citadel Advisors first reported a position in European Biotech Acquisition Corp. Units in Q1 2021 and held it in 1 quarter.
  • Citadel Advisors's European Biotech Acquisition Corp. Units position peaked at $6.28M in Q1 2021.
  • 37 funds tracked by Wall St. Rank held European Biotech Acquisition Corp. Units as of Q2 2021.

Based on Citadel Advisors's 13F filing for Q2 2021, filed 16 Aug 2021.